Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from across its Prime Editing pipeline and platform at the upcoming European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, being held October 22-25, 2024 in Rome, and the American Association for the Study of Liver Diseases (AASLD), being held November 15-19, 2024 in San Diego.
“At the ESGCT and AASLD meetings, we will present new preclinical data from across our pipeline, including from our efforts in liver disease,” said Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer of Prime Medicine. “We are particularly excited to share in vivo data from our Wilson’s Disease program, as well as from our universal liver-directed lipid nanoparticle (LNP) platform. Together, these data reinforce our strategy of prioritizing Wilson’s Disease – a large, genetically defined condition for which there are no currently approved disease-modifying treatments, and which we believe is uniquely suited to a Prime Editing-based approach – and reinforce the potential for our modular universal LNP to be used broadly across current and future programs. We look forward to advancing our Wilson’s Disease program into IND-enabling studies later this year and, longer term, to potentially leveraging the modularity of our platform to expand into numerous follow-on indications.”
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around core areas of focus: hematology, immunology and oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities.
